Benchmark Reiterates Hold Rating on RXO, Inc. (RXO) Following Jury Verdict in Lipe v. Lupus Superior
Benchmark analyst Christopher Kuhn reiterated a Hold rating on RXO, Inc. (NYSE: RXO).The analyst commented, "RXO's valuation has become more ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
